61st Annual Scientific Meeting of the American Headache Society
POSTER PRESENTATIONS
Friday, July 12 and Saturday, July 13, 2019

P01  Central Mechanisms of Cortical Spreading Depression Inhibition by Vagus Nerve Stimulation
     Morais, Andreia

P02  Cortical Spreading Depression Inhibition by Non-invasive Vagus Nerve Stimulation: Dose-response and
     Duration of Effect
     Morais, Andreia

P03  Early Life Stress-induced Increases in Cortical Spreading Depression Susceptibility and Anxiety Are Not
     Expressed in the Progeny of Stressed Male Rats
     Collins, Stuart

P04  Maternal Separation-induced Increases in CrhR1 Expression Within the Occipital Cortex and
     Hippocampus
     Collins, Stuart

P05  Early Life Stress Promotes Development of a Sensitized Trigeminal System and Gut Dysbiosis That Is
     More Severe in Females
     Durham, Paul

P06  Noninvasive Vagus Nerve Stimulation and Morphine Transiently Inhibit Trigeminal Pain Signaling in a
     Chronic Migraine Model
     Durham, Paul

P07  The Role of Cerebellar CGRP in Migraine-like Behavior
     Wang, Mengya

P08  Effect of Yoga as Add on Therapy in Migraine (CONTAIN): A Randomized Controlled Study
     Kumar, Anand

P09  CGRP Antibodies as Adjunctive Prophylactic Therapy for Prolonging the Therapeutic Effect of
     OnabotulinumtoxinA Injections Among Chronic Migraine Patients
     Yuan, Heidi

P10  A Real-world Assessment of the Impact on the Health-related Quality of Life and Work Productivity of
     Triptan Non-responders Compared with Responders: Results from a Global Study
     Lombard, Louise

P11  Early Detection of Persons at Risk for Incident CM
     Iaconangelo, Charles

P12  Eptinezumab Reduces the Frequency of Headaches and Migraines in Patients with Episodic or Chronic
     Migraine: Results from the PROMISE 1 and PROMISE 2 Trials
     Mechtler, Laszlo
OnabotulinumtoxinA is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study
Rothrock, John

The Impact of OnabotulinumtoxinA vs Placebo on Efficacy Outcomes in Responder and Nonresponder Subgroups of Patients with Chronic Migraine: PREEMPT Pooled Analysis
Diener, Hans-Christoph

Multiple Sclerosis and Headache: A Further Examination of These Comorbid Conditions in Patients Receiving Care in a Multiple Sclerosis Center: A Cross-Sectional Study
Minen, Mia

Reduced Impact of Headaches After Migraine Preventive Treatment with Eptinezumab in Patients with Chronic Migraine: Results from the PREVAIL Open-Label Safety Study
Spierings, Egilius

Eptinezumab Treatment for Migraine Prevention Reduces Migraine Disability in Patients with Chronic Migraine: An Analysis from the PREVAIL Open-Label Safety Study
Kudrow, David

The Effect of Lacosamide on Chronic Migraine: Retrospective Analysis in a Single Center Academic Headache Center
Yuan, Heidi

Early Prescribing Patterns of the Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies Are Dominated by Adjunctive Use for Episodic and Chronic Migraine Prevention: Trending the First Year of US Adoption
Schobel, Virginia

The Aimovig "Wear-Off": A Retrospective Review
Feldman, Daniel

Patient Engagement and Patient Centered Research: The Results of Four Focus Groups on the Migraine Patient Experience During Research Studies and Their Ideas for Study Design Consideration in Future Studies
Minen, Mia

Impact of US Physicians’ Perceptions of the Distinct Pharmacological and Clinical Characteristics of the Novel Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies on Self-Reported Chronic Migraine Prevention Brand Share
Schobel, Virginia

Effectiveness of Erenumbab-aooe on High Frequency Migraine Patients in a Tertiary Center
Preston, Juliette

Detecting Factors Associated with "low" and “high” Headache Pain Days in Individuals with Chronic Migraine
Donoghue, Stephen

Longitudinal Preventive Medication Use Patterns in Patients Receiving OnabotulinumtoxinA Treatment: A Chart Review Study
Burch, Rebecca
Tolerability of Three Additional Neck Injection Sites During OnabotulinumtoxinA Therapy Following the PREEMPT Injection Paradigm for Chronic Migraine
Khan, Fawad

Up in Smoke: Erenumab Induced Nausea Exacerbated by Smoking Resulting in Smoking Cessation
Mathew, Paul

A Survey of American Headache Society Members on Treatment of Migraine in Pregnancy
Hamilton, Katherine

Elective Hospitalizations for Intractable Headache: Outcomes and Response Predictors
Kiarashi, Jessica

DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Efficacy Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Lipton, Richard

Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD® Device Compared to D.H.E. 45® for Injection from the STOP 101 Clinical Trial
Craig, Karen

The Medication Overuse Treatment Strategy (MOTS) Trial: Description of the Patient Cohort at Baseline
Schwedt, Todd

Galcanezumab Safety/tolerability Profile Does Not Differ in Patients with Episodic or Chronic Migraine
Stauffer, Virginia

Real-World Experience with CGRP-antagonists in the Treatment of Migraine
Bucklan, Julie

Long-Term Safety of Fremanezumab: Results of a 1-Year Study
Ning, Xiaoping

Control of the Placebo Response in Migraine Induction Models
CONNELL, JOHN

Safety, Tolerability and Comparative Pharmacokinetics of a Novel, Dry Powder Intranasal DHE Product (STS101)
Albrecht, Detlef

Post-Market Observational Study of Patient Experience with Erenumab
Robblee, Jennifer

Changes in MIDAS, Perceived Stress, Frontalis Muscle Activity and NSAID Usage in Patients with Migraine Headache Without Aura Following Ayurveda and Yoga Compared to Controls: An Open Labeled Non-randomized Study
Sharma, Vasudha

Treatment of Trigeminal Neuralgia Using the TX360 Device
Freitag, Frederick

Rimegepant 75 Mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine
Croop, Robert

Riboflavin and Micronutrient Deficiencies in Patients with Migraine--A Case Series with Documented Blood Levels and Response to Treatment of Nutritional Deficiencies
Achari, Madhureeta

Sheikh, Huma

The Effectiveness of Essential Oils on Headaches

Shrewsbury, Stephen

STOP 301: Open-label Safety and Tolerability of Chronic Intermittent Usage for 24/52 Weeks of INP104 [Nasal Dihydroergotamine Mesylate (DHE) Administered by Precision Olfactory Delivery (POD®) Device] in Migraine Headache

Sandoe, Claire

The Impact of Shift Work on Migraine: A Case Series and Literature Review

Munjal, Sagar

Safety and Tolerability of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: Safety Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies

Burish, Mark

Cluster Headache Is One of the Most Painful Human Conditions: Epidemiology of Cluster Headache and Probable Cluster Headache from a Large International Sample

Chowdhury, Debashish

Vascular Risk Associations in Cluster Headache: A Case Control Study from India

Singh, Jyotika

The Headache That Broke My Heart

Robblee, Jennifer

Symptomatic SUNA Heralding a Lateral Medullary Infarction: A Case of a Sentinel Trigeminal Autonomic Cephalgia

Lipton, Richard

Prevalence of Gastric Ulcer Disease (UD) and Association with NSAID Use Among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment (MAST) Study

Grosberg, Brian

Understanding Practice Patterns Surrounding the Use of Hormonal Therapies in Migraine: results from the Women’s Health Migraine Survey

Lipton, Richard

Who Is Eligible for Novel Medications Designed for the Acute Treatment of Migraine and What Are Their Unmet Needs? Results of the OVERCOME Study

Lipton, Richard

Impact of Migraine Headache Day Frequency on Associated Health : Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study
P55  Identifying Sociodemographics and Symptoms Associated with Emergency Department and Urgent Care Use in People with Migraine: Survey Results from Migraine in America Symptoms and Treatment Study Schwedt, Todd

P56  Symptom Patterns, Disability, and Physician Visits Among a US Sample of People with Migraine: Results of the OVERCOME Study Reed, Michael

P57  A Real-World Analysis of the Burden of Migraine in Patients with Prior Treatment Failure: Evidence from the BECOME Study Lucas, Christian

P58  Meaningful Relief Measurement: Analysis of Responses to a Survey of Patient Priorities Smith, Timothy

P59  Headache Evaluation and Treatment: results from the Women’s Health Migraine Survey Grosberg, Brian

P60  Evaluating the Relationship of Healthcare Professional-Patient Communication, Treatment and Satisfaction: Results from Migraine in America Symptoms and Treatment Study Buse, Dawn

P61  Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study Alam, Aftab

P62  Characteristics of Migraine Patients Visiting the European Headache Specialist Centers: Real-World Evidence from the Multinational BECOME Study Pozo-Rosich, Patricia

P63  Migraine Prevalence, Disease and Comorbidity Burden, and Evidence-based Practice Guideline Knowledge: results from the Women’s Health Migraine Survey Minen, Mia

P64  Factors Associated with Most Bothersome Non-Headache Migraine Symptom (Nausea, Photophobia and Phonophobia): Results from the Migraine in America Symptoms and Treatment (MAST) Study Munjal, Sagar

P65  Assessment of Prevalence and Knowledge Knowledge of Migraine Headache in Northeast Nigeria Ali, Mohammed

P66  Network Analysis of the International Classification of Headache Disorders, 3rd Edition Zhang, Pengfei

P67  A Surveillance of the Tortuous Path from Primary Care to Headache Specialist Lin, Jason

P68  Prevalence and Incremental Healthcare Costs of Comorbid Depression in Migraine Care Kee, Arianna

P69  Digital Therapeutics Treatment of Migraine Schenker, Eran
P70  Epidemiology of Headache in Latin America: A Systematic Review and Meta-analysis of Its Prevalence and Incidence
Pacheco-Barrios, Kevin

P71  10-Year Cost-Effectiveness Analyses of Fremanezumab as Preventive Treatment in Chronic and Episodic Migraine
Smolen, Lee

P72  A RETROSPECTIVE COMMUNITY BASED STUDY EVALUATING DISABILITY in MIGRAINE PATIENTS TREATED with ERENUMAB-aooe
Turner, Ira

P73  Economic Aspects of Establishing Prior Use of Two Oral Triptans Before Starting Novel Acute Treatments for Migraine
Pohl, Gerhardt

P74  Impact of Migraine on the Prevalence and Clinical Presentation of Depression: A Population-based Study
Chu, Min Kyung

P75  Development of a Patient Reported Outcome Measure Evaluating Meaningful Response to Migraine Treatment
Cady, Ryan

P76  Systematic Review of Clinical Studies Evaluating Non-invasive Neuromodulation for Migraine and Cluster Headache
Reuter, Uwe

P77  Scoping Review of Migraine and Air Pollution Studies
Portt, Andrea

P78  Association of Migraine and Asthma in Pediatric Patients: A National Perspective on Gender and Racial Disparities
Patel, Riddhiben

P79  Benign Paroxysmal Torticollis: Phenotype, Natural History and Future Research Directions
Greene, Kaitlin

P80  Paracetamol versus Ibuprofen for the Acute Treatment of Migraine Headache in Children
VASUDEVAN, PAVITHRA

P81  Pediatric Screen Exposure and Headache Disability
Langdon, Raquel

P82  Efficacy of Sphenopalatine Ganglion Blocks in a Pediatric Headache Practice
Holick, Michelle

P83  Prognosis of New Daily Persistent Headache in Children and Adolescents
Simmons, Adrienne

P84  Title: Headache Prevalence in Transgender Youth: A Retrospective Chart Review
Hranilovich, Jennifer

P85  Headache Frequency in Children After Hemispherectomy
The Experience of One Headache Center’s Launch of the New CGRP Migraine Medications
Wells, Rebecca

P100
Absence of Clinically Significant Drug Interactions with Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis
Li, Chi-Chung

P101
Pressing Issues Among New Investigators and Trainees in Headache: Results of a Survey of the American Headache Society New Investigator and Trainee Section and International Headache Academy Attendees
VanderPluym, Juliana

P102
A Proposed Structure for the Study of the History of Headache Medicine
Rosen, Noah

P103
Ubrogepant Achieves Onset of Pain Relief at 1 Hour for the Acute Treatment of Migraine
Dodick, David

P104
Onset of Efficacy Following Oral Treatment with Lasmiditan for the Acute Treatment of Migraine
Vasudeva, Raghavendra

P105
Efficacy and Safety of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the Multicenter, Randomized, Placebo-controlled FOCUS Study
Ferrari, Michel

P106
Effect of a Rescue or Recurrence Dose of Lasmiditan on Efficacy and Safety in the Acute Treatment of Migraine: Findings from the Phase 3 Trials (SAMURAI and SPARTAN)
Loo, Li Shen

P107
Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Silberstein, Stephen

P108
Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine
Rizzoli, Paul

P109
Long-term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine Attacks
Ailani, Jessica

P110
Long-term Response Rates in Chronic and Episodic Migraine Patients with Concomitant Preventive Medication Use: Results from 1-Year Study
Goadsby, Peter

P111
Temporal Response Patterns to Erenumab in Patients with Chronic Migraine
Tepper, Stewart

P112
An Optional Second Dose of Ubrogepant Is Effective in Achieving 2-Hour Pain Freedom in the Acute Treatment of Migraine
Ailani, Jessica
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>P113</td>
<td>Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study</td>
<td>Goadsby, Peter</td>
</tr>
<tr>
<td>P114</td>
<td>Effects of Lasmiditan on Cardiovascular Parameters in Healthy Subjects Receiving Oral Doses of Propranolol</td>
<td>Wilbraham, Darren</td>
</tr>
<tr>
<td>P115</td>
<td>Patient Functioning and Disability Among Patients with Migraine: Evaluation of Galcanezumab in a Long-Term, Open-Label Study</td>
<td>McAllister, Peter</td>
</tr>
<tr>
<td>P116</td>
<td>Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab Among Patients with Episodic and Chronic Migraine</td>
<td>Wietecha, Linda</td>
</tr>
<tr>
<td>P117</td>
<td>Efficacy of Erenumab in Chronic Migraine Patients with and Without Allodynia</td>
<td>Lipton, Richard</td>
</tr>
<tr>
<td>P118</td>
<td>Long-Term Efficacy of Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification</td>
<td>Lipton, Richard</td>
</tr>
<tr>
<td>P119</td>
<td>Improvement in Migraine Pain Severity in Patients Treated with Erenumab</td>
<td>Lipton, Richard</td>
</tr>
<tr>
<td>P120</td>
<td>How Adverse Events Are Collected and Reported: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan</td>
<td>Krege, John</td>
</tr>
<tr>
<td>P121</td>
<td>Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy</td>
<td>Buchanan, Andrew</td>
</tr>
<tr>
<td>P122</td>
<td>Shift from Chronic Migraine to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab</td>
<td>Hindiyeh, Nada</td>
</tr>
<tr>
<td>P123</td>
<td>Long-Term Impact of Fremanezumab on Response Rates: Results of a 1-Year Study</td>
<td>Newman, Lawrence</td>
</tr>
<tr>
<td>P124</td>
<td>Safety of Ubrogepant in Participants with Moderate to High Cardiovascular Risk</td>
<td>Hutchinson, Susan</td>
</tr>
<tr>
<td>P125</td>
<td>PREVAIL: An Open-Label Phase 3 Trial to Evaluate the Safety of Eptinezumab Administered Intravenously in Patients with Chronic Migraine</td>
<td>Allan, Brent</td>
</tr>
<tr>
<td>P126</td>
<td>Temporal Response Patterns to Erenumab in Patients with Episodic Migraine</td>
<td>McAllister, Peter</td>
</tr>
<tr>
<td>P127</td>
<td>Real-world Use of Non-invasive Vagus Nerve Stimulation for Acute Treatment of Pain in Episodic Cluster Headache: Results from a Patient Registry</td>
<td>Liebler, Eric</td>
</tr>
</tbody>
</table>
The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Headaches of at Least Moderate Severity in Patients with Chronic Migraine
Silberstein, Stephen

Long-term Efficacy of Fremanezumab in Migraine Patients with and Without Concomitant Oral Preventive Medication Use: Results of a 1-Year Study
Goadsby, Peter

Long-Term Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Migraine Patients with Concomitant Preventive Medication Use: Results of a 1-Year Study
Lipton, Richard

Improvement in Response over Time with Fremanezumab in Patients Who Reverted from a Chronic to an Episodic Migraine Classification
Halker Singh, Rashmi

Healthcare Resource Utilization in Adult Patients Treated with OnabotulinumtoxinA for Chronic Migraine: Results from the COMPEL Study
Rothrock, John

Efficacy and Safety of Lasmiditan in Patients on Concomitant Migraine Preventive Medications: Findings from SAMURAI and SPARTAN Phase 3 Trials
Schim, Jack

Comparison of Early Plasma Exposure of DHE Following Nasal, Oral Inhalation, or Intravenous Administration
Satterly, Kelsey

Efficacy Is Maintained with Long-term Intermittent Use of Ubrogepant for the Acute Treatment of Migraine
Lipton, Richard

Improvement in Headache-related Disability with Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Migraine Preventive Medication Classes in the International, Multicenter, Randomized FOCUS Study
Ashina, Messoud

Sustained Response to Erenumab over Time in Patients with Episodic Migraine
McAllister, Peter

Eptinezumab Improved Health-Related Quality of Life in Patients with Chronic Migraine in the Open-Label PREVAIL Study
Kassel, Eric

The Impact of Fremanezumab on the Maximum Number of Consecutive Days Without Migraine in Patients with Episodic Migraine
Dodick, David

Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Chronic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
Silberstein, Stephen
<table>
<thead>
<tr>
<th>Paper ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P141</td>
<td>Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study</td>
<td>Lipton, Richard</td>
</tr>
<tr>
<td>P142</td>
<td>Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine: Results of a 1-Year Study</td>
<td>McAllister, Peter</td>
</tr>
<tr>
<td>P143</td>
<td>Long-Term Impact of Fremanezumab on Headache-Related Disability, Quality of Life, and Patient Satisfaction in Episodic Migraine and Chronic Migraine</td>
<td>Cohen, Joshua</td>
</tr>
<tr>
<td>P144</td>
<td>Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine and Comorbid Moderate to Severe Depression</td>
<td>Lipton, Richard</td>
</tr>
<tr>
<td>P145</td>
<td>Effects of Lasmiditan When Coadministered with Sumatriptan: Results of a Randomized, Double-Blind, Crossover Study in Healthy Subjects</td>
<td>Berg, Paul</td>
</tr>
<tr>
<td>P146</td>
<td>Effects of Lasmiditan When Coadministered with Topiramate: Results of a Parallel, Placebo-Controlled, Fixed-Sequence Study in Healthy Subjects</td>
<td>Berg, Paul</td>
</tr>
<tr>
<td>P147</td>
<td>Long-Term Impact of Fremanezumab on Headache-Related Disability and Quality of Life in Patients Who Reverted from a Chronic to an Episodic Migraine Classification</td>
<td>Ailani, Jessica</td>
</tr>
<tr>
<td>P148</td>
<td>Safety and Tolerability Outcomes of the Multicenter, Randomized, Placebo-controlled FOCUS Study of Fremanezumab in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications</td>
<td>Ferrari, Michel</td>
</tr>
<tr>
<td>P149</td>
<td>Long-Term Efficacy of Fremanezumab in Patients with Chronic Migraine with Concomitant Preventive Medication Use</td>
<td>Goadsby, Peter</td>
</tr>
<tr>
<td>P150</td>
<td>Sustained Response to Erenumab over Time in Patients with Chronic Migraine</td>
<td>Tepper, Stewart</td>
</tr>
<tr>
<td>P151</td>
<td>Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study</td>
<td>Winner, Paul</td>
</tr>
<tr>
<td>P152</td>
<td>Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed at Least One Prior Preventive Migraine Medication: Results of a 1-Year Study</td>
<td>McAllister, Peter</td>
</tr>
<tr>
<td>P153</td>
<td>Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed at Least One Prior Preventive Migraine Medication: Results of a 1-Year Study</td>
<td>Brandes, Jan</td>
</tr>
</tbody>
</table>
P154  Ubrogepant for the Acute Treatment of Migraine: Pooled Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3 Studies
Hutchinson, Susan

P155  Quarterly Administration of Fremanezumab Does Not Show “Wearing Off” Effect During Third Month After Injection
Blaiss, Cory

P156  The Effect of Migraine Headache Intensity of the Efficacy of Low-Dose (3 Mg) Sumatriptan Injection (DFN-11) in the Acute Treatment of Episodic Migraine Attacks: From the RESTOR Study
Munjal, Sagar

P157  Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
Brandes, Jan

P158  An Open-Label Phase 3 Trial to Evaluate the Safety of Eptinezumab Administered Intravenously in Patients with Chronic Migraine (PREVAIL): Demographics and Baseline Characteristics
Song, Yanyu

P159  Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Results of a 1-Year Study
Brandes, Jan

P160  Depression and Anxiety Are Associated with Increased Headache-Related Disability in Episodic and Chronic Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
Lipton, Richard

P161  Features of Episodic Cluster Headache in the Real World Setting: Clinical Characteristics from a Large, Multi-national, Cross-sectional Survey
Martinez, James

P162  Characteristics of Headaches and Premonitory Symptoms During the Run-in Phase of a Large Migraine Trial
Schmidt, Peter

P163  Healthcare Resource Use and Humanistic Burden Associated with Attack Frequency in Episodic Cluster Headache
Andrews, J. Scott

P164  Characteristics of Patients Receiving Preventive Treatment Among Prevention-eligible Patients with Migraine
Mason, Oksana

P165  Characteristics of Early Users of Erenumab in a Large US Administrative Claims Database
Chia, Victoria

P166  Dihydroergotamine, Then and Now
Ray, Sutapa

P167  The Association Between Migraine Headache and Objectively-assessed Sleep Among Adults with Episodic Migraine: A Prospective Cohort Study
Vgontzas, Angeliki

P168 Does Treatment of Cervical Dystonia Reduce Migraine Frequency?  
Bobker, Sarah

P169 Thoracic CSF Venous Fistula Presenting as Spontaneous Intracranial Hypotension  
Duvall, Jaclyn

P170 Migraine History and Effectiveness of Caffeine Use in Hypnic Headache Patients  
Preston, Juliette

P171 Non-Invasive Vagus Nerve Stimulation as a Rescue Treatment for Vestibular Migraine  
Beh, Shin

P172 Observations from a Collaborative Care Headache and Hormone Clinic Model  
Grosberg, Brian

P173 A Novel Perivascular Approach to the Ultrasound-guided Glossopharyngeal Nerve Block  
Anugerah, Ariana

P174 Persistent Neurological Deficits in a Patient with CACANA1A Gene Revealing Diffuse Astrocytoma  
Suneja, Aarushi

P175 One and Done: A Case Series of Large Volume Occipital Nerve Blocks for the Treatment of Occipital Neuralgia  
Mathew, Paul

P176 Neuropathic Otalgia: Rare and Treatable Ear Pains  
Suneja, Aarushi

P177 Red Ear Syndrome Case Report: A Rational Use of Erenumab  
Robblee, Jennifer

P178 Diffuse Vasogenic Leakage of Gadolinium Contrast in Patients with Syndrome of Headache and Neurological Deficits with CSF Lymphocytosis (HANDL)  
Vilanilam, George

P179 Novel Receptor Activity Mapping of Methysergide and Its Metabolite, Methylergometrine, Provides a Mechanistic Rationale for Both the Clinically Observed Efficacy and Risk of Fibrosis in Patients with Migraine  
Guzman, Miguel

P180 Serotonin Receptor Activity Profiles (5-HT2B and 5-HT2A) for Nine Commercialized Ergot Alkaloids Correspond to Known Risks of Fibrosis and Hallucinations  
Alam, Aftab

P181 Calcitonin Gene-related Peptide Inhibitor; Role in Treatment of Hemicrania Continua, with Potential Benefit in Controlling Diarrhea  
Hussaini, Sharmeen

P182 Development of a Novel, Clinical-stage Drug for the Prevention of Migraine Based on Receptor Activity Mapping and Achievement of a Target Receptor Profile  
Armer, Thomas
Post-Traumatic Headache Is Highly Persistent over Time After TBI in Veterans
Couch, James

Sports-related Concussion in High School Wrestlers: Survey of Wrestlers and Their Parents
Goldberg, Marco

Understanding the Prevalence and Geographic Distribution of Headache Disorders Within the Veterans Health Administration
Grinberg, Amy

New Persistent Post-Concussion Headache in Children and Adolescents
Barissi, Marcus

Introducing a Nationwide Program to Improve the Care of Veterans with Headache – the Veterans Health Administration Headache Center of Excellence (HCoE) Program
Sico, Jason

Results of a Gap Analysis of Headache in Veterans and Service Members
Lindsey, Hayley

Dextromethorphan/Quinidine for Post Traumatic Migraine in Patients with Pseudobulbar Affect
Kozinski, Matthew

Rationale and Design for a Randomized, Single-Center, Double-blind, Sham-Controlled Study of Non-invasive Vagus Nerve Stimulation for the Acute and Preventive Treatment of Post-traumatic Headache
Vargas, Bert

Objectively Measured Physical Activity Among Migraineurs as a Function of Headache Activity
Rogers, Daniel

Feasibility and Acceptability of Smartphone Based Migraine Behavioral Therapy in The Neurology Outpatient Setting: A Single Arm Study
Minen, Mia

The Use of Mindfulness-Based Cognitive Therapy (MBCT) for Migraine for the Treatment of Depressive Symptoms in People with Migraine: Secondary Analysis Results from a Phase 2b Pilot Randomized Clinical Trial
Rosenberg, Lauren

Does Message Framing Help with Willingness to Pursue Behavioral Therapy: A Study in People with Migraine
Jalloh, Adama

Does Motivational Interviewing Improve Patients’ Participation in Migraine Behavioral Therapy: A Pilot Single-Blinded Randomized Controlled Trial
Minen, Mia

Relationship Between Age of Onset and Psychological Factors in Migraine Patients
Sutton, Leah

Development and Implementation of “The Migraine Toolbox”
bernstein, carolyn
Integrating Physical and Mental Health in Patients with Headache: Bridging the Gap via a Transdisciplinary and Interprofessional Approach
Amorello, Brian

Assessing Diagnostic Error in Cerebral Vein Thrombosis via Detailed Chart Review
Liberman, Ava

A Rare Case of Bilateral Internal Carotid Artery Aneurysms Presenting as Trigeminal Neuralgia
Muzammil, Syeda maria

The Presence of Headache Attributed to TMD Is Associated with Greater Psychiatric Comorbidity in Patients with Chronic TMD
Vivaldi, Daniela

Migraine Treatments Utilized by Postural Orthostatic Tachycardia Syndrome Patients
Fayyaz, Tabbassum

Squamous Cell Carcinoma as a Delayed Presentation of Supraorbital Neuralgia and Multiple Cranial Neuropathies: A Case Report
Robblee, Jennifer

“Ear Burn” as a Positional Manifestation of Gastroesophageal Reflux Disease
Arca, Karissa

Recurrent Thunderclap Headache from a Sexual Performance Enhancing Agent Marketed as All-natural
Sallowm, Yamin

Lumbar CSF Pressure vs Volume Studies May Provide Clues to Occult Underlying Pathology Associated with Headache
Lucchese, Scott

Headaches in a HIV Patient
Varma-Doyle, Aditi

The function of the brain that turn dysfunctional in migraine and related functional disorders
Hougaard, Kjeld

Analgesic effect of intranasal oxytocin in a rat model of trigeminal neuralgia
Yeomans, David

The Aimovig “Wear-Off”: A Retrospective Case Series of Response to 14 day Dosing
George, Naveen

IV Valproate Sodium as a Preventive Treatment for Chronic Migraine
Riggins, Nina

Prognosis following discontinuation of onabotulinumtoxinA therapy in "super-responding" chronic migraine patients
Rothrock, John

Content validity of the HIT-6 in migraine patients: results of a systematic literature review
Houts, Carrie
P214LB Chronic migraine: Establishing a responder definition for the HIT-6 total score
Cady, Roger

P215LB Eptinezumab Demonstrated Early and Sustained Reductions in HIT-6 Total Score Over Time in Patients with Chronic Migraine in the PROMISE-2 Trial
Lipton, Richard

P216LB Early and Sustained Reduction in Headache Impact in People with CM After Eptinezumab Treatment: HIT-6 Item Analysis in the Phase 3 PROMISE-2 Trial
Buse, Dawn

P217LB Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
Winner, Paul

P218LB Eptinezumab Reduces the Frequency of Acute Medication Usage in Patients with Episodic or Chronic Migraine
Tepper, Stewart

P219LB Treatment with Eptinezumab Demonstrated Meaningful Improvements in Patients with Chronic Migraine Experiencing a High Frequency of Severe Migraines
Nagy, Abraham

P220LB The Eptinezumab: CGRP Complex Structure and Characterization of the Ligand Binding Interface
Misura, Kira

P221LB Development of nasal insulin-like growth factor-1 as a novel treatment for migraine
Kraig, Richard

P222LB Use of Single Pulse Transcranial Magnetic Stimulation (sTMS) to treat migraine with medication overuse: response over time
DiGuilio, Susan

P223LB Chronic Migraine is Highly Prevalent in General Otolaryngology; A CHEER Network Study
Teixido, Michael

P224LB Is stress associated with pain severity in chronic migraine?
Donoghue, Stephen

P225LB A Patient perspective of Complementary and Integrative Medicine (CIM) for Migraine Treatment: A social media survey
Kuruvilla, Deena

P226LB A retrospective analysis to evaluate the response of the addition of erenumab to onabotulinumtoxinA for the prevention of intractable chronic migraine without aura
Armanious, Mark

P227LB Facial temperature change after Sphenopalatine ganglion block in Primary Headache Disorders
Mathew, Shema

P228LB Migraine Modifies Propranolol Efficacy for Treatment of TMD Pain: SOPPRANO Randomized Controlled Trial
Limited antinociceptive effects of delta-9-tetrahydrocannabinol in experimental models of capsaicin-induced hyperalgesia and acute pain in healthy human volunteers
Schindler, Emmanuelle

Assessing the Long-Term Effectiveness of Qtrypta using the Migraine-ACT: Correlation with Electronic Diary Scores
Tepper, Stewart

Individual-level patterns of perceived stress throughout the migraine cycle: A longitudinal cohort study using daily prospective data
Shulman, Kenneth

A pilot randomized controlled trial of a community-based mindfulness-based stress reduction intervention versus usual care for moderate-to-severe migraine headache
Pressman, Alice

Occipital neuralgia: clinical profile and sleep quality of 55 Mexican patients. Results from PREMECEF.
Marfil, Alejandro

Effectiveness of a Novel algorithm in the treatment of chronic migraine by reduction of work hour loss due absenteeism and presentism.
OWIESY, FARO

Long-Term, Open-Label Safety Study of Rimegepant 75 mg for the Treatment of Migraine (Study 201): Interim Analysis of Safety and Exploratory Efficacy
Lipton, Richard

Rimegepant 75 mg is Effective for the Acute Treatment of Migraine Regardless of Attack Frequency: Results From 3 Phase 3 Trials
Buse, Dawn

Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays
Conway, Charles

Acute Treatment Benefit from Oral CGRP Receptor Antagonist and Monoclonal Antibody Combination: Rimegepant 75 mg for Acute Treatment of Attacks During Preventive Therapy With Erenumab
Mullin, Kathleen

Rimegepant is Effective for the Acute Treatment of Migraine in Subjects Taking Concurrent Preventive Medication: Results From 3 Phase 3 Trials
Dodick, David

The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
Croop, Robert

Rimegepant 75 mg in Subjects with Hepatic Impairment: Results of a Phase 1, Open-label, Single-dose, Parallel-group Study
Croop, Robert
P242LB  A Single Dose of Rimegepant 75 mg Provides Pain Relief and Return to Normal Function: Results from 3 Phase 3 Trials in Adults With Migraine
Lipton, Richard

P243LB  The Safety and Tolerability of Rimegepant 75 mg Are Similar to Placebo: Results from 3 Phase 3 Trials in Adults With Migraine
Hutchinson, Susan

P244LB  A Single Dose of Rimegepant Demonstrates Sustained Efficacy and Low Rescue Medication Use in the Acute Treatment of Migraine: Results From 3 Phase 3 Trials
Pavlovic, Jelena

P245LB  Rimegepant Has No Clinically Relevant Effects on ECG parameters: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects
Hanna, Michael

P246LB  Rimegepant 75 mg Is More Effective Than Nonsteroidal Anti-inflammatory Drugs for the Acute Treatment of Migraine: Post Hoc Analysis of Data From 2 Phase 3 Trials
Blumenfeld, Andrew

P247LB  Safety of Rimegepant 75 mg in Adults With Migraine: No Effects of Age, Sex, or Race in 3 Phase 3 Trials
Hutchinson, Susan

P248LB  Impact of galcanezumab on total pain burden: findings from a Phase 3 randomized, double-blind, placebo-controlled study in patients with episodic cluster headache
Kuruppu, Dulanji

P249LB  Galcanezumab treatment patterns in episodic cluster headache: findings from a Phase 3b multicenter, single-arm, open-label safety study of galcanezumab
Oakes, Tina

P250LB  Is there an epidemic of chronic tension type headache in Washington, DC?
Rothrock, John

P251LB  Association and Impact of Monthly Migraine Headache Frequency and Pain Intensity on Comorbidities and Concomitant Health Conditions: Results from the Migraine in America Symptoms and Treatment (MAST) Study
Munjal, Sagar

P252LB  Headache Frequency, Disability, Treatment Optimization and Medication Use Patterns in Persons with Migraine and Co-morbid Gastric Ulcer Disease (UD): Results from Migraine in America Symptoms and Treatment (MAST) Study
Singh, Preeti

P253LB  The Migraine Patient Journey: Diagnosis and Treatment Patterns in a Large Healthcare System, Results of the Migraine Signature Study (MSS)
Pressman, Alice

P254LB  Direct Headache Care: Patient Outcomes Using A Membership Based, Integrative Model
Wohlgehagen, Cristina
Impact of Monthly Headache Day Frequency on Work Productivity and Impairment in Non-Work Activities among Persons with Migraine: Results from the Migraine in America Symptoms and Treatment Study
Munjal, Sagar

New Daily Persistent Headaches in a Pediatric Population
DiSabella, Marc

An app to help children describe their headache. Results of the first clinical trial.
Nava, Nelly

Trajectory of Pediatric Migraine Preventive Medication Treatment Response: An Ancillary Study of the CHAMP Trial
Reidy, Brooke

Post-hoc outcomes from a Phase 3 randomized, double-blind, placebo-controlled study of galcanezumab in patients with episodic cluster headache
Martinez, James

Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study
Reuter, Uwe

A Real Headache, Professional Subjects in Migraine Trials
Shiovitz, Thomas

Dysgeusia rates in a multicenter, open-label, long-term, safety study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for acute treatment of migraine
Munjal, Sagar

Triptan-related adverse events in a multicenter, open-label, long-term, safety study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of migraine
Brand-Schieber, Elimor

Evaluation of the Number of Migraine Headache Days and Hours in Subjects Using DFN-02 for Acute Treatment in a Long Term Open-label safety study
Munjal, Sagar

Daily and Economic Burden of Living with Migraine: United States Results from the “My Migraine Voice” Survey
Shah, Shweta

User Acceptance of a Prefilled Auto-injector Device for Erenumab in Patients with Migraine
Mead, Jennifer

Is chocolate associated with more severe days in chronic migraine?
Shulman, Kenneth

Early Use of Erenumab in US Real World Practice
Chia, Victoria

Erenumab prescription early view: Patient characteristics, treatment patterns and medication adherence in the United States
Shah, Shweta

Treatment patterns, healthcare resource use, and outcomes of patients with chronic and episodic migraines treated with erenumab: a multicenter chart-review study
Chandler, David

Patient satisfaction with fremanezumab treatment for chronic or episodic migraine: results from a web-based, patient survey following completion of a 1-year extension study
Lipton, Richard

Simulated Use of a Fremanezumab Autoinjector: Use as Intended, Ease of Use, and Comfort with Using the Autoinjector
Cowen, Robert

Patient preference for dosing regimen and perception of dosing flexibility with fremanezumab for chronic or episodic migraine: results from a web-based, patient survey following completion of a 1-year extension study
Cowen, Robert

A rare case of nervus intermedius neuralgia responsive to sphenopalatine ganglion blocks
Joseph, Rosamma

Rare Cause of Worsening Migraine with Aura: Iatrogenic Atrial Septal Defect Following Cardiac Ablation
Thaler, Alison

The Effect of Aimovig on Trigeminal Neuralgia: A Retrospective Case Series
George, Naveen

Migraine Features Associated with Postural Orthostatic Tachycardia Syndrome (POTS)
Mueller, Bridget

The degree of discomfort provoked by flickering light is strongly related to visual cortex response
Patterson Gentile, Carlyn

Phase 1 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range
Conway, Charles

Response to Mindfulness-Based Cognitive Therapy for Migraine in Chronic and Episodic Migraine: Planned Secondary Analyses of a Randomized Clinical Trial
Seng, PhD, Elizabeth

Spontaneous Intracranial Hypotension (SIH) Secondary to CSF Venous Fistula: Case Series
Duvall, Jaclyn

Risk Factors for Secondary Headache in Children and Adolescents: A Systematic Review
Velasquez, Gerardo